Who
Michael John Tomsicek
Director
Company insider
Files Form 4 as: Director, Acrivon Therapeutics; Director, Milestone Pharmaceuticals; Chief Financial Officer, CRISPR Therapeutics AG; Vice President, CFO, Abiomed; SVP & Chief Financial Officer, Cubist Pharmaceuticals.
In numbers
- Trades disclosed
- 102
- Buys
- 1
- Sells
- 9
- Bought
- $80K
- Sold
- $5.8M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 28 Mar 2013
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,275 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,275 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,000 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —9,366 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —9,366 at $0.00 | filing |
| 13 Jun 2025filed 17 Jun 2025 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,275 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 28 Aug 2024filed 29 Aug 2024 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,275 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 14 Nov 2022filed 16 Nov 2022 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,235 at $0.00 | filing |
| 19 Oct 2022filed 21 Oct 2022 | MIST Milestone PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $80K15,000 at $5.32 | filing |
| 5 Jul 2022filed 11 Aug 2022 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 6 Aug 2021filed 10 Aug 2021 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | $444K25,000 at $17.75 | filing |
| 6 Aug 2021filed 10 Aug 2021 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $2.6M19,011 at $138.22 | filing |
| 6 Aug 2021filed 10 Aug 2021 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $835K5,989 at $139.46 | filing |
| 14 Jun 2021filed 29 Jul 2021 | MIST Milestone Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Mar 2021filed 10 Aug 2021 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 11 Mar 2021filed 12 Mar 2021 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —25,360 at $0.00 | filing |
News
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology ConferencesMIST · manilatimes.net · 19 Oct 2026Where Will CRISPR Therapeutics Stock Be in 2030?CRSP · aol.com · 18 Oct 2026Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.CRSP · aol.com · 18 Oct 2026Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $51,230.40 in StockCRSP · themarketsdaily.com · 18 Oct 2026Head-To-Head Analysis: Milestone Pharmaceuticals (NASDAQ:MIST) & Bristol Myers Squibb (NYSE:BMY)MIST · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Michael John Tomsicek; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.